Allogene Therapeutics (ALLO) Registration filing summary

Company overview and business model

• Clinical-stage immuno-oncology company developing allogeneic T cell therapies for cancer and autoimmune diseases.

• Pipeline focuses on “off-the-shelf” T cell products derived from healthy donors, aiming for scalable, rapid, and broad patient access.

• Incorporated in Delaware in 2017, headquartered in South San Francisco, CA.

Use of proceeds and capital allocation

• Net proceeds intended for general corporate purposes, including clinical trial, R&D, administrative expenses, and capital expenditures.

• May allocate funds to in-license, invest in, or acquire complementary businesses, assets, or technologies, though no current commitments exist.

• Pending use, proceeds will be invested in investment-grade, interest-bearing instruments.

Risk factors and disclosures

• Investment involves a high degree of risk, with risks detailed in the prospectus, supplements, and incorporated SEC filings.

• Risks include adverse effects on business, operating results, financial condition, and potential loss of investment.

• Additional unknown or currently immaterial risks may also impact operations.